Green Cross Corp
006280
Company Profile
Business description
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.
Contact
303 Bojeong-Dong
Giheung-Gu
YonginGyeonggi449-070
KORT: +82 312609300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,355
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,007.00 | 65.50 | 0.73% |
| CAC 40 | 7,744.41 | 53.81 | -0.69% |
| DAX 40 | 24,041.90 | 265.90 | -1.09% |
| Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
| FTSE 100 | 9,023.81 | 10.82 | 0.12% |
| HKSE | 25,460.54 | 330.51 | 1.32% |
| NASDAQ | 20,892.69 | 81.49 | -0.39% |
| Nikkei 225 | 41,307.01 | 1,532.09 | 3.85% |
| NZX 50 Index | 12,794.06 | 39.68 | -0.31% |
| S&P 500 | 6,309.62 | 4.02 | 0.06% |
| S&P/ASX 200 | 8,743.60 | 66.40 | 0.77% |
| SSE Composite Index | 3,596.68 | 14.82 | 0.41% |